Connect with us


COVID-19: Commission authorizes third adapted vaccine for member states' autumn vaccination campaigns




We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Commission has authorized the Nuvaxovid XBB.1.5-adapted COVID-19 vaccine, developed by Novavax. This is another important step in the fight against the disease. It is the first protein-based adapted vaccine authorized for this autumn and winter season.

The European Medicines Agency (EMA) carried out an in-depth evaluation of the vaccine. Following this evaluation, the Commission authorised the adapted vaccine under an expedited procedure so that member states have sufficient time to prepare for their autumn-winter vaccination campaigns.

In line with previous recommendations by the EMA and the European Centre for Disease Prevention and Control (ECDC), adults and adolescents from 12 years of age who require vaccination are invited to get a single dose, irrespective of their COVID-19 vaccination history.


With the EU Vaccines Strategy, the Commission continues to ensure that member states have access to the latest authorised COVID-19 vaccines to protect the vulnerable members of their population and deal with the epidemiological evolution of the virus.

Novavax has adapted its COVID-19 vaccine to target the SARS-CoV-2 Omicron strain XBB.1.5. This is in line with ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 variants. The adapted vaccine is also expected to increase the breadth of immunity against current dominant and emerging variants.

More information


Commission authorisation

EMA recommendation

EU Vaccines Strategy

Safe COVID-19 vaccines for Europeans

EU Coronavirus Response

Overview of the Commission's Response

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.